1 of 1
Story summary
- On September 9, 2025, President Trump signed an executive memorandum to improve regulation of direct-to-consumer pharmaceutical advertising for better transparency and accuracy.
- The FDA will enforce stricter compliance, issuing approximately 100 cease-and-desist letters and thousands of warning notices to drug companies for misleading advertisements.
- Health Secretary Robert F. Kennedy Jr. called the initiative a "historic change," aiming to restore pre-1997 advertising rules requiring full disclosure of side effects.
- The FDA will also target deceptive social media promotions, where only one-third mention potential harms.
- Kennedy stressed the importance of "radical transparency" to address overmedicalization and its effects on public health.
